PMID- 35568824
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20220716
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 22
IP  - 1
DP  - 2022 May 14
TI  - An immune-related lncRNA pairs signature to identify the prognosis and predict 
      the immune landscape of laryngeal squamous cell carcinoma.
PG  - 545
LID - 10.1186/s12885-022-09524-1 [doi]
LID - 545
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is the most common squamous 
      cell carcinoma. Though significant effort has been focused on molecular 
      pathogenesis, development, and recurrence of LSCC, little is known about its 
      relationship with the immune-related long non-coding RNA (lncRNA) pairs. METHODS: 
      After obtaining the transcriptome profiling data sets and the corresponding 
      clinical characteristics of LSCC patients and normal samples from The Cancer 
      Genome Atlas (TCGA) database, a series of bioinformatic analysis was conducted to 
      select the differently expressed immune-related lncRNAs and build a signature of 
      immune-related lncRNA pairs. Then, the effectiveness of the signature was 
      validated. RESULTS: A total of 111 LSCC patients and 12 normal samples' 
      transcriptome profiling data sets were retrieved from TCGA. 301 differently 
      expressed immune-related lncRNAs were identified and 35,225 lncRNA pairs were 
      established. After univariate Cox analysis, LASSO regression and multivariate Cox 
      analysis, 7 lncRNA pairs were eventually selected to construct a signature. The 
      riskscore was computed using the following formula: 
      Riskscore = 0.95 x (AL133330.1|AC132872.3) + (-1.23)  
      x (LINC01094|LINC02154) + 0.65 x (LINC02575|AC122685.1) + (-1.15)  
      x (MIR9-3HG|LINC01748) + 1.45 x (AC092687.3|SNHG12) + (-0.87)  
      x (AC090204.1|AL158166.1) + 0.64 x (LINC01063|Z82243.1). Patients were classified 
      into the high-risk group (> 1.366) and the low-risk group (< 1.366) according to 
      the cutoff value (1.366), which is based on the 5-year riskscore ROC curve. The 
      survival analysis showed that the low-risk group had a better prognosis 
      (P < 0.001). The riskscore was better than other clinical characteristics in 
      prognostic prediction and the area under the curves (AUCs) for the 1-, 3-, and 
      5-year survivals were 0.796, 0.946, and 0.895, respectively. Combining age, 
      gender, grade, stage, and riskscore, a nomograph was developed to predict 
      survival probability in LSCC patients. Then, the riskscore was confirmed to be 
      related with the content of tumor-infiltration immune cells and the model could 
      serve as a potential predictor for chemosensitivity. CONCLUSION: We successfully 
      established a more stable signature of 7 immune-related lncRNA pairs, which has 
      demonstrated a better prognostic ability for LSCC patients and may assist 
      clinicians to precisely prescribe chemo drugs.
CI  - (c) 2022. The Author(s).
FAU - Qian, Lvsheng
AU  - Qian L
AD  - Department of Otolaryngology, Affiliated Hospital of Nantong University, Nantong, 
      226001, Jiangsu, China.
FAU - Ni, Tingting
AU  - Ni T
AD  - Department of Oncology, Nantong Tumor Hospital, Nantong, 226001, Jiangsu, China.
FAU - Fei, Bing
AU  - Fei B
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Affiliated Huai'an 
      Hospital of Xuzhou Medical University, Huai'an, 223002, Jiangsu, China.
FAU - Sun, Hui
AU  - Sun H
AD  - Department of Pathology, Affiliated Hospital of Nantong University, Nantong, 
      226001, Jiangsu, China.
FAU - Ni, Haosheng
AU  - Ni H
AD  - Department of Otolaryngology, Affiliated Hospital of Nantong University, Nantong, 
      226001, Jiangsu, China. entnhs@ntu.edu.cn.
LA  - eng
GR  - No.2020Z136/Postdoctoral Science Foundation of Jiangsu Province/
GR  - No.2020Z136/Postdoctoral Science Foundation of Jiangsu Province/
GR  - No.2020Z136/Postdoctoral Science Foundation of Jiangsu Province/
GR  - No.2020Z136/Postdoctoral Science Foundation of Jiangsu Province/
GR  - No.2020Z136/Postdoctoral Science Foundation of Jiangsu Province/
PT  - Journal Article
DEP - 20220514
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Gene Expression Profiling
MH  - Humans
MH  - *Laryngeal Neoplasms/genetics
MH  - Prognosis
MH  - *RNA, Long Noncoding/genetics
MH  - *Squamous Cell Carcinoma of Head and Neck/genetics
PMC - PMC9107277
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma (LSCC)
OT  - Long non-coding RNA (lncRNA)
OT  - Prognostic signature
OT  - The Cancer Genome Atlas (TCGA)
OT  - Tumor-infiltrating immune cell
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/16 06:00
MHDA- 2022/05/19 06:00
PMCR- 2022/05/14
CRDT- 2022/05/15 00:24
PHST- 2021/06/20 00:00 [received]
PHST- 2022/04/08 00:00 [accepted]
PHST- 2022/05/15 00:24 [entrez]
PHST- 2022/05/16 06:00 [pubmed]
PHST- 2022/05/19 06:00 [medline]
PHST- 2022/05/14 00:00 [pmc-release]
AID - 10.1186/s12885-022-09524-1 [pii]
AID - 9524 [pii]
AID - 10.1186/s12885-022-09524-1 [doi]
PST - epublish
SO  - BMC Cancer. 2022 May 14;22(1):545. doi: 10.1186/s12885-022-09524-1.